PepGen

50 articles about PepGen

• PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology

  9/27/2023

  PepGen Inc. announced that it will be presenting at the 28th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina.

• PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences

  9/6/2023

  PepGen Inc. today announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023.

• PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1

  9/6/2023

  PepGen Inc. announced it has received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1.

• PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

  9/1/2023

  PepGen Inc. announced that it will be presenting at upcoming medical meetings and an investor conference.

• PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

  8/8/2023

  PepGen Inc. today reported financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.

• PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

  6/13/2023

  PepGen Inc. (Nasdaq: PEPG) today announced that while it awaits receipt of an official clinical hold letter from the U.S. Food and Drug Administration (FDA), the Company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023 in any geography.

• 

  FDA Puts Clinical Hold on PepGen’s DM1 Early-Stage Trial

  5/31/2023

  The regulator will provide PepGen with a letter within 30 days explaining why a clinical hold was placed on the company’s Phase 1 study of patients with myotonic dystrophy Type 1.

• PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

  5/30/2023

  PepGen Inc. (Nasdaq: PEPG) today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) to initiate a Phase 1 study of PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1).

• PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

  5/18/2023

  PepGen Inc. today announced that the company has received a No Objection Letter (NOL) for its Clinical Trial Application (CTA) from Health Canada for its Phase 2 CONNECT1-EDO51 study to initiate an open label, multiple ascending dose (MAD) clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51 skipping approach.

• PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

  5/11/2023

  PepGen Inc. reported financial results for the first quarter ended March 31, 2023.

• PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

  5/4/2023

  PepGen Inc.  today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the Bank of America Securities 2023 Healthcare Conference on Thursday, May 11th at 12:20pm EDT in Las Vegas, Nevada.

• PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

  4/17/2023

  PepGen Inc. (Nasdaq: PEPG) today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts.

• PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

  4/13/2023

  PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20th at 8:00am EDT.

• PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments

  3/23/2023

  PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments.

• PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference

  3/22/2023

  PepGen Inc. (Nasdaq: PEPG) will be presenting today nonclinical and clinical data of its Enhanced Oligonucleotide Delivery (EDO) platform at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas, Texas.

• PepGen to Participate in the Stifel 2023 CNS Days Conference

  3/21/2023

  PepGen Inc. (Nasdaq: PEPG) today announced that James McArthur, Ph.D., President and CEO of PepGen will present at Stifel’s CNS Days Conference on Tuesday, March 28th at 1:30pm EST.

• PepGen to Participate in the SVB Securities Global Biopharma Conference

  2/9/2023

  PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at SVB Securities’ Global Biopharma Virtual Conference on Thursday, February 16th 2023, at 10:40 A.M. EST.

• PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

  12/7/2022

  PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced new preclinical data supporting the progression of PGN-EDODM1, PepGen’s product candidate in development for the treatment of myotonic dystrophy type 1 (DM1), into clinical trials.

• 

  Recession Survival Strategies for Newly Public Biopharma Companies

  11/28/2022

  Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.
• 

  Three Influential Women in Biopharma Explain How to Break the Executive Barrier

  11/17/2022

  According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.